Young at heart — but how old is your body? This startup has raised $4.2m to help you find out

UK biotech GlycanAge picks $4.2M seed funding for its age-defying technology predicting diseases — TFN

GlycanAge, a UK longevity startup, has raised a $4.2m seed round led by LAUNCHub Ventures and Kadmos Capital. The company provides users with a finger prick test kit that measures their biological age using biomarkers for glycans. The company also offers individual consultation with a specialist who suggests ways to slow down the ageing process. GlycanAge plans to shift away from the longevity space to the broader diagnostics market, aiming to develop disease-specific tests that catch illnesses early.

GlycanAge Raises $4.2M to Measure Biological Age

GlycanAge is a UK longevity startup that helps users learn their biological age by measuring biomarkers for glycans, complex carbohydrate molecules and one of the primary components of our bodies’ cells. The company says that glycobiology can help with predicting diseases, guiding interventions and tailoring therapies. It provides users with a finger prick test kit sent directly to their home, where the sample undergoes multiple tests in the laboratory for about three weeks. The user will also receive various indexes related to their age — such as cardio health and gut health — to identify potential risks and areas for improvement. GlycanAge also offers users individual consultation with a specialist who suggests how they could slow down their ageing process. One-off treatment costs £289.

GlycanAge is a UK longevity startup that measures users' biological age with biomarkers for glycans and provides individual consultation with a specialist to suggest ways to slow down the ageing process.

a year ago

GlycanAge Raises $4.2M to Measure Biological Age

ProblemHealthcare

Solution

Covered on